Acerta Pharma Bv
Clinical trials sponsored by Acerta Pharma Bv, explained in plain language.
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-phase study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to see if the combination is safe and effective. Participant…
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the drugs worked together. Researchers measured side effects and tumor…
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Promising combo tackles tough blood cancers
Disease control CompletedThis early-phase study tested a combination of two drugs, acalabrutinib and obinutuzumab, in 69 people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal was to see if the combination was safe and could shrink or eliminate cancer. Participants included tho…
Phase: PHASE1 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug shows promise for Tough-to-Treat leukemia
Disease control CompletedThis study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a specific genetic change (deletion 17p). The goal was to see how well the drug controls the cancer. Participants took acalabrutinib pil…
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 20, 2026 11:55 UTC